EGCG promotes apoptosis in BT-549 triple-negative breast cancer cells by targeting STAT3

Key Points

Apoptosis is significantly induced in BT-549 cells by EGCG, revealing potential therapeutic effects.
Inhibition of STAT3-driven signaling pathways leads to reduced migration and cell proliferation effects.
Analysis of EGCG's impact demonstrates modulation of key apoptotic pathways linked to cancer cell survival.
Findings highlight the need for further studies to explore EGCG as a clinical treatment option for TNBC.

Abstract

EGCG effectively suppresses STAT3-driven oncogenic signaling in TNBC by inhibiting cell proliferation, reducing migration, and inducing apoptosis through the modulation of key apoptotic pathways. Thus, EGCG could be a promising therapeutic candidate for targeting STAT3-mediated mechanisms in TNBC. Further research should be conducted to examine the clinical application of EGCG.

EGCG promotes apoptosis in BT-549 triple-negative breast cancer cells by targeting STAT3

Key Points

Abstract

Cite This Study